Evoke Pharma, Inc. (EVOK)
USD 2.21
(0.45%)
USD 2.21
(0.45%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -7.29 Million USD | 3.8% |
| 2022 | -7.72 Million USD | 5.14% |
| 2021 | -8.03 Million USD | 37.56% |
| 2020 | -13.04 Million USD | -82.29% |
| 2019 | - USD | 15.31% |
| 2018 | - USD | 17.38% |
| 2017 | - USD | 8.23% |
| 2016 | - USD | 3.24% |
| 2015 | -11.51 Million USD | 12.36% |
| 2014 | -13.13 Million USD | -406.43% |
| 2013 | -2.59 Million USD | -29.68% |
| 2012 | -1.99 Million USD | 16.77% |
| 2011 | -2.4 Million USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | -1.22 Million USD | 0.0% |
| 2024 Q1 | -1.5 Million USD | 100.0% |
| 2023 FY | - USD | 3.8% |
| 2023 Q3 | -1.56 Million USD | 10.06% |
| 2023 Q2 | -1.74 Million USD | 17.76% |
| 2023 Q4 | -1.88 Million USD | -20.41% |
| 2023 Q1 | -2.11 Million USD | -26.39% |
| 2022 FY | - USD | 5.14% |
| 2022 Q2 | -2.1 Million USD | -2.85% |
| 2022 Q1 | -2.05 Million USD | -32.6% |
| 2022 Q3 | -1.88 Million USD | 10.47% |
| 2022 Q4 | -1.67 Million USD | 11.16% |
| 2021 Q3 | -1.84 Million USD | 14.89% |
| 2021 FY | - USD | 37.56% |
| 2021 Q1 | -2.58 Million USD | -17.16% |
| 2021 Q2 | -2.16 Million USD | 16.28% |
| 2021 Q4 | -1.54 Million USD | 16.12% |
| 2020 Q3 | -2.07 Million USD | 70.15% |
| 2020 Q2 | -6.96 Million USD | -288.28% |
| 2020 Q1 | -1.79 Million USD | -25.95% |
| 2020 FY | - USD | -82.29% |
| 2020 Q4 | -2.2 Million USD | -6.24% |
| 2019 Q4 | -1.42 Million USD | 12.98% |
| 2019 Q1 | -1.96 Million USD | -11.39% |
| 2019 Q2 | -2.12 Million USD | -7.81% |
| 2019 Q3 | -1.63 Million USD | 22.93% |
| 2019 FY | - USD | 15.31% |
| 2018 Q4 | -1.76 Million USD | -16.15% |
| 2018 Q3 | -1.52 Million USD | 33.98% |
| 2018 FY | - USD | 17.38% |
| 2018 Q1 | -2.85 Million USD | 43.08% |
| 2018 Q2 | -2.3 Million USD | 19.11% |
| 2017 FY | - USD | 8.23% |
| 2017 Q4 | -5 Million USD | -132.14% |
| 2017 Q3 | -2.15 Million USD | 48.03% |
| 2017 Q2 | -4.15 Million USD | -480.0% |
| 2017 Q1 | 1.09 Million USD | 135.01% |
| 2016 Q3 | -1.97 Million USD | 30.25% |
| 2016 FY | - USD | 3.24% |
| 2016 Q2 | -2.82 Million USD | 8.28% |
| 2016 Q1 | -3.08 Million USD | -24.3% |
| 2016 Q4 | -3.12 Million USD | -58.38% |
| 2015 Q4 | -2.47 Million USD | 6.74% |
| 2015 Q2 | -3.16 Million USD | 8.14% |
| 2015 Q1 | -3.44 Million USD | -18.21% |
| 2015 Q3 | -2.65 Million USD | 16.01% |
| 2015 FY | - USD | 12.36% |
| 2014 Q2 | -3.48 Million USD | -19.53% |
| 2014 Q3 | -3.81 Million USD | -9.48% |
| 2014 Q4 | -2.91 Million USD | 23.73% |
| 2014 FY | - USD | -406.43% |
| 2014 Q1 | -2.91 Million USD | -76.29% |
| 2013 Q4 | -1.65 Million USD | -215.58% |
| 2013 Q1 | -330.67 Thousand USD | 49.57% |
| 2013 FY | - USD | -29.68% |
| 2013 Q2 | -202.55 Thousand USD | 38.75% |
| 2013 Q3 | -524.59 Thousand USD | -158.99% |
| 2012 FY | - USD | 16.77% |
| 2012 Q1 | -501.65 Thousand USD | 0.0% |
| 2012 Q2 | -360.16 Thousand USD | 28.2% |
| 2012 Q3 | -479.29 Thousand USD | -33.08% |
| 2012 Q4 | -655.67 Thousand USD | -36.8% |
| 2011 FY | - USD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Collegium Pharmaceutical, Inc. | 308.32 Million USD | 102.365% |
| Embecta Corp. | 245.4 Million USD | 102.972% |
| ANI Pharmaceuticals, Inc. | 109.32 Million USD | 106.671% |
| Dynavax Technologies Corporation | 9.66 Million USD | 175.443% |
| Esperion Therapeutics, Inc. | -150.1 Million USD | 95.142% |
| Pacira BioSciences, Inc. | 162.89 Million USD | 104.477% |
| PainReform Ltd. | -9.56 Million USD | 23.793% |
| Aquestive Therapeutics, Inc. | 1.18 Million USD | 716.945% |
| Sunshine Biopharma, Inc. | -3.82 Million USD | -90.677% |
| SCYNEXIS, Inc. | 73.47 Million USD | 109.924% |
| China SXT Pharmaceuticals, Inc. | -2.35 Million USD | -210.177% |
| Cosmos Health Inc. | -17.06 Million USD | 57.26% |
| Journey Medical Corporation | 1.92 Million USD | 479.609% |
| Sunshine Biopharma, Inc. | -3.82 Million USD | -90.677% |
| Safety Shot Inc | -12.18 Million USD | 40.154% |
| Alpha Teknova, Inc. | -25.53 Million USD | 71.446% |
| Intra-Cellular Therapies, Inc. | -158.85 Million USD | 95.409% |
| Bright Green Corporation | - USD | Infinity% |
| Procaps Group, S.A. | 104.02 Million USD | 107.01% |
| Theratechnologies Inc. | -10.31 Million USD | 29.289% |
| Harrow Health, Inc. | 9.72 Million USD | 175.0% |
| Sonoma Pharmaceuticals, Inc. | -4.52 Million USD | -61.156% |
| Biofrontera Inc. | -18.45 Million USD | 60.482% |
| DURECT Corporation | -24.68 Million USD | 70.457% |
| Supernus Pharmaceuticals, Inc. | 98.26 Million USD | 107.421% |
| Cronos Group Inc. | -72.14 Million USD | 89.893% |
| OptiNose, Inc. | -15.55 Million USD | 53.113% |
| Ironwood Pharmaceuticals, Inc. | -924.86 Million USD | 99.212% |
| Kala Pharmaceuticals, Inc. | -36.08 Million USD | 79.79% |
| RedHill Biopharma Ltd. | 26.26 Million USD | 127.763% |
| Organogenesis Holdings Inc. | 36.03 Million USD | 120.239% |
| Guardion Health Sciences, Inc. | -3.92 Million USD | -85.916% |
| Cumberland Pharmaceuticals Inc. | -710.85 Thousand USD | -925.856% |
| Radius Health, Inc. | 38.31 Million USD | 119.035% |
| Universe Pharmaceuticals INC | -3.21 Million USD | -126.816% |
| ProPhase Labs, Inc. | -14.82 Million USD | 50.817% |
| Phibro Animal Health Corporation | 84.6 Million USD | 108.619% |
| Procaps Group S.A. | 104.02 Million USD | 107.01% |
| Alvotech | -484.86 Million USD | 98.496% |
| TherapeuticsMD, Inc. | -8.4 Million USD | 13.197% |
| Viatris Inc. | 3.51 Billion USD | 100.207% |
| Rockwell Medical, Inc. | -4.69 Million USD | -55.354% |
| Aytu BioPharma, Inc. | -1.01 Million USD | -620.583% |
| SIGA Technologies, Inc. | 84.15 Million USD | 108.665% |
| Tilray Brands, Inc. | -72.84 Million USD | 89.989% |
| Lifecore Biomedical, Inc. | 812 Thousand USD | 998.066% |
| Shineco, Inc. | -26.55 Million USD | 72.538% |
| PetIQ, Inc. | 81.48 Million USD | 108.949% |
| Regencell Bioscience Holdings Limited | -3.61 Million USD | -101.577% |
| Incannex Healthcare Limited | -18.5 Million USD | 60.591% |
| Neurocrine Biosciences, Inc. | 416.1 Million USD | 101.753% |
| Alimera Sciences, Inc. | 7.27 Million USD | 200.224% |
| Silver Spike Investment Corp. | 7.34 Million USD | 199.349% |
| Assertio Holdings, Inc. | -222.44 Million USD | 96.722% |
| Shuttle Pharmaceuticals Holdings, Inc. | -3.99 Million USD | -82.735% |
| Petros Pharmaceuticals, Inc. | -4.21 Million USD | -73.137% |
| Clever Leaves Holdings Inc. | -16.8 Million USD | 56.604% |
| Cyclo Therapeutics, Inc. | -20.03 Million USD | 63.595% |
| Avadel Pharmaceuticals plc | -149.12 Million USD | 95.11% |
| Hempacco Co., Inc. | -12.77 Million USD | 42.91% |
| Talphera, Inc. | -9.84 Million USD | 25.906% |
| Alvotech | -484.86 Million USD | 98.496% |
| Eagle Pharmaceuticals, Inc. | 77.5 Million USD | 109.409% |
| Lantheus Holdings, Inc. | 491 Million USD | 101.485% |
| Currenc Group, Inc. | -1.9 Million USD | -283.689% |
| Kamada Ltd. | 21.53 Million USD | 133.864% |
| Indivior PLC | 66 Million USD | 111.049% |
| Flora Growth Corp. | -45.87 Million USD | 84.102% |
| Cyclo Therapeutics, Inc. | -20.03 Million USD | 63.595% |
| Evolus, Inc. | -41.81 Million USD | 82.558% |
| HUTCHMED (China) Limited | 25.52 Million USD | 128.566% |
| Amphastar Pharmaceuticals, Inc. | 241.46 Million USD | 103.02% |
| Akanda Corp. | -27.73 Million USD | 73.708% |